

Claim 9, line 7, delete "(XXII)", and insert therefor --(SEQ ID NO:52)--.

Claim 9, line 10, delete "(XXIII)", and insert therefor --(SEQ ID NO:53)--.

RB
10. (Amended) Nucleic acid from claim 9, which further comprises [furthermore encompasses] a CDR1 and/or CDR2 region selected from a nucleotide sequence which encodes the amino acid sequence of SEQ ID NO:124, 125, 80, 81, 100, 101, 122 or 116 [sequences shown in Tab. 7a or b] or an amino acid sequence which is at least 80% homologous thereto.

REMARKS

In this amendment, applicants have amended the specification by deleting pages 49-72 containing the original sequence listing, renumbering the pages containing the claims accordingly, and inserting a revised Sequence Listing as pages i-xlii at the end of the application. In accordance with 37 CFR 1.821 et seq, applicants have amended the claims by inserting SEQ ID NO: in the appropriate places. It is respectfully submitted that the foregoing amendments and remarks place the application in compliance with 37 CFR 1.821 through 1.825 and no new matter is contained in this amendment.

Enclosed is a computer-readable sequence listing in MS-DOS format on a 3.5" disk.

In the event this paper is not timely filed, applicants hereby petition for an appropriate extension of time. The fee for this extension may be charged to our Deposit Account No. 01-2300, along with any other additional fees which may be required with respect to this paper.



Respectfully submitted,
ARENT FOX KINTNER PLOTKIN & KAHN PLLC

King L. Wong

King L. Wong

Registration No. 37,500

Atty. Docket No. 100564-09049
1050 Connecticut Ave. N.W.
Suite 600
Washington, D.C. 20036-5339
Tel: (202) 857-6000

Enclosures: New pages i-xlii containing the revised Sequence Listing;
Computer diskette containing computer readable form of
Sequence Listing; and
Statement under 37 CFR 1.821